ugt-60 Antibody
Product Specs
Constituents: 50% Glycerol, 0.01M Phosphate Buffered Saline (PBS), pH 7.4
Target Background
Q&A
UGT enzymes (UDP-glucuronosyltransferases) play critical roles in drug metabolism and cancer biology, with antibody-based research providing key insights into their complex mechanisms. Below are structured FAQs addressing both foundational and advanced research considerations, supported by empirical evidence from recent studies.
How to validate UGT antibody specificity for isoform-specific research?
Stepwise protocol:
-
Immunoprecipitation (IP): Confirm target capture (e.g., 57 kDa band in human liver homogenate using ab129729) .
-
Cross-reactivity testing: Compare reactivity across UGT1A (50–60 kDa) and UGT2B (55–58 kDa) isoforms via Western blot .
-
Functional assays: Measure glucuronidation activity in UGT-overexpressing cell lines (e.g., HEK293) normalized to protein levels .
Critical controls:
-
Negative controls: Knockout cell lines or siRNA-mediated UGT suppression.
How to resolve contradictory data on UGT’s role in non-substrate drug resistance?
Case example: UGT1A6 correlates with nivolumab (anti-PD-1 antibody) resistance despite lacking direct conjugation activity .
Analytical framework:
-
Mechanistic hypotheses:
-
Validation steps:
-
CRISPR-Cas9 knockout of UGT1A6 in resistant models.
-
Metabolomic profiling to identify UGT-linked pathways.
-
Data reconciliation table:
| Observation | Proposed Mechanism | Supporting Evidence |
|---|---|---|
| UGT1A6↑ in non-responders | Indirect metabolite regulation | 5–7.1-fold mRNA increase |
| No direct drug conjugation | Immune pathway modulation | IHC validation |
What multi-omics strategies enhance UGT biomarker discovery?
Integrated workflow:
-
Transcriptomics: RNA-seq of tumor biopsies to identify UGT1A/2B clusters linked to progression-free survival .
-
Proteomics: SRM/MRM mass spectrometry to quantify UGT isoforms in formalin-fixed samples .
-
Pharmacogenomics: Germline UGT1A128 genotyping paired with irinotecan pharmacokinetics .
Data integration example:
| Omics Layer | Technology | Key Finding |
|---|---|---|
| Transcriptomic | NanoString | UGT1A6↑ in 8/12 renal carcinoma non-responders |
| Proteomic | IHC | 65% vs. 23% UGT1A6+ cells (non-responders vs. responders) |
What criteria prioritize UGT antibodies for functional studies?
Selection matrix:
Validation priority:
-
Functional correlation: Link antibody signal to enzymatic activity (e.g., SN-38 glucuronidation rate) .
How to address UGT heterogeneity in clinical trial design?
Strategies:
-
Pre-screening: Enroll patients with UGT1A1*28 polymorphism for irinotecan trials .
-
Dynamic monitoring: Serial liquid biopsies to track UGT induction during HSP90 inhibitor therapy .
Trial endpoint example:
